A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

Sponsor
Jin LI
Study ID
NCT07466901
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    200mg, intravenous drip for 0.5h, Q3W
  • famotinib — DRUG
    10mg, oral administration, QD

Study Details

This study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.

Key Dates

Start date
Apr 1, 2026
Status verified
Jan 2026
Primary completion
Apr 1, 2030
Completion
Aug 31, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: camrelizumab combined with famotinib
    Camrelizumab combined with famitinib for adjuvant therapy after radical resection of cervical cancer

Primary Outcome Measure

2-year disease-free survival rate [ Time Frame: 2 years after treatment ]

Central Contacts

Related Studies